Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Noninvasive spinal cord stimulation to help glucose control in adults with and without spinal cord injury

Official title: Effects of Noninvasive Spinal Cord Neuromodulation on Metabolic Function

Run by University of Kentucky · NCT07597161 · Data updated 2026-11-12

This study tests whether noninvasive transcutaneous spinal cord stimulation can improve glucose regulation in adults with normal, prediabetic, or type 2 diabetic glucose levels, including people with spinal cord injury.

More Spinal Cord Injuries (SCI) trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment120 (estimated)
SponsorUniversity of Kentucky
Academic / other
Locations1 site (Lexington, Kentucky)
StatusRecruiting
StartedOctober 20, 2026
Main results expectedMay 31, 2030
Study endsDecember 2030
Registry record updatedOctober 29, 2026
Trial IDNCT07597161 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18 and older with chronic spinal cord injury (T6 or above or AIS A-D) or able-bodied, and with normal glucose metabolism, prediabetes, or type 2 diabetes.

Probably not a fit

Individuals with conditions or circumstances that preclude safe tSCS or that do not respond to neuromodulation may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study will evaluate the acute and chronic effects of transcutaneous spinal cord stimulation (tSCS) on glucose metabolism in adults with and without spinal cord injury. Participants will receive active tSCS or sham stimulation to assess changes in glucose and insulin responses during an oral glucose tolerance test, as well as longer-term measures such as HbA1c, insulin sensitivity, and metabolic biomarkers. The trial aims to determine feasibility, safety, and potential metabolic benefits across a spectrum of metabolic states. Primary outcomes focus on glucose and insulin responses, while secondary outcomes explore broader metabolic changes. The study is conducted at a single site in Lexington, Kentucky, led by a researcher team with no listed collaborators.

Why it matters

Potential benefit: If successful, participants could experience improved glucose regulation and metabolic health, potentially reducing diabetes risk or progression.

How similar studies have gone: Recent neuromodulation efforts targeting metabolic function have shown promising signals, but this specific noninvasive tSCS approach remains exploratory.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants must be at least 18 years of age and able to provide informed consent.

  * Chronic spinal cord injury (at least 1 year post-injury) with neurological level of injury T6 or above, classified as AIS A-D, or able-bodied individuals without a history of spinal cord injury or neurological disorder
  * Participants must meet criteria for normal glucose metabolism, prediabetes, or type 2 diabetes, determined using HbA1c, fasting plasma glucose, fasting insulin, or oral glucose tolerance testing (OGTT). Normal glucose metabolism is defined as HbA1c less than 5.7% and fasting plasma glucose less than or equal to 100 mg/dL. Impaired glucose metabolism (prediabetes or type 2 diabetes) will be identified by HbA1c greater than or equal to 5.7%, fasting plasma glucose greater than100 mg/dL (5.6 mmol/L), fasting insulin greater than 8.5-10 µIU/mL after at least 8 hours of fasting, or 2-hour plasma glucose greater than 140 mg/dL (7.8 mmol/L) during a standard OGTT performed using a 75 g anhydrous glucose load dissolved in water.
  * Participants taking diabetes medications may be included if their medication regimen has been stable for at least 12 weeks before enrollment. This ensures observed metabolic changes are attributable to tSCS rather than recent medication adjustments. Medication use will be documented and included as a covariate in analyses to account for potential effects

Exclusion Criteria:

* Unstable medical conditions (e.g., cardiac disease, active infections).

  * Implanted devices (e.g., pacemakers, neurostimulators, ITB pumps).
  * Change of medications that alter glucose metabolism (e.g., corticosteroids).
  * Frequent, symptomatic hypoglycemia.
  * Inability to tolerate stimulation procedures or complete study protocols.
  * Diagnosis of Type 1 diabetes mellitus.
  * Skin breakdown, eczema, or other dermatological conditions (e.g., psoriasis) affecting the skin at the site of electrodes placement.
  * Females who are pregnant, breastfeeding, or intend to become pregnant.
  * Cognitive impairments, social/psychological problems, or other comorbid conditions that, in the opinion of the Investigator, will preclude them from participation.

Where it's running

  • Department of Physical Medicine and Rehabilitation-Research Suite
    Lexington, Kentucky, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.